What is Spexis?
Headquartered in Allschwil, Switzerland, Spexis is dedicated to the development and manufacturing of pharmaceutical products targeting underserved therapeutic areas. Its strategic focus on rare diseases, oncology, and combating antimicrobial resistance positions the company at the forefront of innovation in addressing significant global health challenges. The company's commitment to these specialized fields highlights its potential for substantial impact and growth within the pharmaceutical sector.
How much funding has Spexis raised?
Spexis has raised a total of $21.7M across 4 funding rounds:
Unspecified
$3.1M
Unspecified
$3.1M
Debt
$11M
Other Financing Round
$4.5M
Unspecified (2019): $3.1M, investors not publicly disclosed
Unspecified (2019): $3.1M, investors not publicly disclosed
Debt (2021): $11M supported by Vectura Group
Other Financing Round (2023): $4.5M, investors not publicly disclosed
Key Investors in Spexis
Vectura Group
Vectura Group is likely a strategic partner or investor focused on pharmaceutical development and manufacturing, given its domain. Their participation suggests a shared interest in advancing Spexis's therapeutic pipeline.
What's next for Spexis?
With the recent infusion of major strategic capital, Spexis is poised for accelerated growth and enhanced operational capabilities. This significant backing is expected to fuel further research and development initiatives, potentially expanding its pipeline of novel therapies and strengthening its market presence. The company's trajectory suggests a move towards scaling its manufacturing capacity and broadening its commercial reach, solidifying its position as a key player in its specialized pharmaceutical niches.
See full Spexis company page
